CoinUnited.io

Tag: VRTX

  • Vertex Pharmaceuticals: A Decade of Growth and Promising Future Ahead

    Vertex Pharmaceuticals: A Decade of Growth and Promising Future Ahead

    Vertex’s Continued Growth in Core Area Vertex Pharmaceuticals has made remarkable strides in the treatment of cystic fibrosis (CF) over the past decade. The company’s monopoly in developing drugs that target the underlying causes of CF has established its dominance in the market. Nevertheless, there are still significant opportunities ahead. Out of the 88,000 eligible […]

  • Vertex Pharmaceuticals Gives Editas Breathing Room with Licensing Deal

    Vertex Pharmaceuticals Gives Editas Breathing Room with Licensing Deal

    A Break for Young Biotechs On December 13, Vertex announced a non-exclusive licensing agreement with Editas for its Cas-9 gene-editing technology. This agreement specifically covers Vertex’s gene therapy for sickle cell disease, Casgevy, developed in collaboration with CRISPR Therapeutics and recently approved by the FDA. Under the agreement, Vertex will pay $50 million upfront, an […]

  • Unstoppable Trends in AI and Gene Editing Present Promising Investment Opportunities

    Unstoppable Trends in AI and Gene Editing Present Promising Investment Opportunities

    The Role of AI in Amazon’s Success Amazon (AMZN 1.73%) is widely recognized as an e-commerce giant that delivers packages swiftly, often on the same day as the order. Behind their operational efficiency and seamless fulfillment processes lies the integration of AI technology. While Amazon has been leveraging AI for some time, the company has […]

  • Vertex’s Painkiller Shows Promise in Mid-Stage Trial, Boosting Stock by 40%

    Vertex’s Painkiller Shows Promise in Mid-Stage Trial, Boosting Stock by 40%

    Potential for Blockbuster Drug Status Analysts anticipate that if VX-548 gains approval from regulators, it could become a blockbuster drug with annual sales surpassing $1 billion. Vertex is now focused on pushing the drug into a late-stage trial, a crucial step closer to regulatory approval. Additionally, the company is conducting late-stage studies to assess its […]

  • Vertex vs. Exact: Unicorns in the Evolving Healthcare Sector

    Vertex vs. Exact: Unicorns in the Evolving Healthcare Sector

    Vertex: Leading in Cystic Fibrosis Therapeutics Vertex has firmly established itself as a dominant player in therapeutics for cystic fibrosis (CF) – a genetically based condition with limited treatment options. With strong pricing power, robust demand, and few competitors in this space, Vertex has built a strong position. Notably, their latest product, Trikafta, accounts for […]

  • 2 Biotech Stocks That Could Give You a Lifetime of Security

    2 Biotech Stocks That Could Give You a Lifetime of Security

    Over the past year, the stock prices of Vertex Pharmaceuticals (VRTX 1.99%) and Regeneron Pharmaceuticals (REGN 1.72%) have each increased by around 20%. Over the past three years, the sales and profits per share (EPS) of the biotech businesses have grown, and they have blooming pipelines that should continue to fuel development. Despite their profitability […]

  • Last year, this growth stock destroyed the market. Five Words from the CEO Indicate More to Come

    Last year, this growth stock destroyed the market. Five Words from the CEO Indicate More to Come

    The business was poised to provide regulators with a promising and maybe blockbuster prospect. Even better, the approval of exa-cel, a candidate for blood diseases, would demonstrate that Vertex was capable of succeeding in markets unrelated to the treatment of cystic fibrosis (CF). Investors may now ask if the positive news has been included into […]